Search Result

Isoforms Recommended:	PLK3

Results for "

PLK3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (2) Apoptosis (6) Autophagy (4) Btk (2) c-Myc (1) JAK (2) Organoid (2) PI3K (2) Polo-like Kinase (PLK) (23) Reference Standards (1) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (19) Cardiovascular Disease (1) Inflammation/Immunology (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15161

Ro3280 4 Publications Verification	Polo-like Kinase (PLK)	Cancer
Ro3280 is a potent, highly selective inhibitor of *PLK1* with an IC₅₀ and a K_d of 3 nM and 0.09 nM, respectively, and nearly has no effect on PLK2 and PLK3.

HY-108597

TC-S 7005 4 Publications Verification	Polo-like Kinase (PLK)	Cardiovascular Disease Inflammation/Immunology
TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC₅₀s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively .

HY-15158

SBE13 Hydrochloride	Polo-like Kinase (PLK) Autophagy Apoptosis	Cancer
SBE13 Hydrochloride is a potent and selective *Plk1* inhibitor, with an IC₅₀ of 200 pM; SBE13 Hydrochloride poorly inhibits Plk2 (IC₅₀>66 μM) or Plk3 (IC₅₀=875 nM).

HY-11003

GW843682X 5 Publications Verification GW843682	Polo-like Kinase (PLK)	Cancer
GW843682X is a selective, ATP-competitive inhibitor of *PLK1* and *PLK3, with IC₅₀*s of 2.2 nM and 9.1 nM, respectively, and is also >100-fold selective against ～30 other kinases.

HY-18009

(Z)-LFM-A13 3 Publications Verification	Btk Polo-like Kinase (PLK) JAK	Cancer
LFM-A13 is a potent BTK, JAK2, *PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.

HY-10197

Wortmannin Maximum Cited Publications 139 Publications Verification SL-2052; KY-12420	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic	Cancer
Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible *PI3K* inhibitor with an IC₅₀ of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and *Plk3* with IC₅₀s of 5.8 and 48 nM, respectively ^[3].

HY-RS10718

Plk3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Polo-like Kinase (PLK)	Others
Plk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Plk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Plk3 Mouse Pre-designed siRNA Set A Plk3 Mouse Pre-designed siRNA Set A

HY-RS10717

PLK3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Polo-like Kinase (PLK)	Others
PLK3 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PLK3 Human Pre-designed siRNA Set A PLK3 Human Pre-designed siRNA Set A

HY-RS10719

Plk3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Polo-like Kinase (PLK)	Others
Plk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Plk3 Rat Pre-designed siRNA Set A Plk3 Rat Pre-designed siRNA Set A

HY-15158A

SBE13	Polo-like Kinase (PLK) Autophagy	Cancer
SBE13 is a potent and selective *Plk1* inhibitor, with an IC₅₀ of 200 pM; SBE13 poorly inhibits Plk2 (IC₅₀>66 μM) or Plk3 (IC₅₀=875 nM).

HY-12137A

Volasertib trihydrochloride BI 6727 trihydrochloride	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .

HY-12137

Volasertib 25+ Cited Publications BI 6727	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .

HY-110002

LFM-A13 1 Publications Verification	Polo-like Kinase (PLK) Btk JAK	Cancer
LFM-A13 is a potent BTK, JAK2, *PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research ^[3]

HY-10197R

Wortmannin (Standard) SL-2052 (Standard); KY-12420 (Standard)	Organoid Reference Standards PI3K Polo-like Kinase (PLK) Autophagy Antibiotic	Cancer
Wortmannin (Standard) is the analytical standard of Wortmannin. This product is intended for research and analytical applications. Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively ^[3].

HY-15160A

TAK-960 hydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 hydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 hydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 hydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-15160B

TAK-960 dihydrochloride 2 Publications Verification	Polo-like Kinase (PLK)	Cancer
TAK-960 dihydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 dihydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 dihydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-115589

YLT-11	Polo-like Kinase (PLK) Apoptosis	Cancer
YLT-11 is a potent, selective and orally active *PLK4* inhibitor with K_d values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity .

HY-15160

TAK-960 2 Publications Verification	Polo-like Kinase (PLK)	Cancer
TAK-960 is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-172364

PLK1-IN-12	Polo-like Kinase (PLK)	Cancer
PLK1-IN-12 is a highly selective and orally active *PLK1* inhibitor with an IC₅₀ of 20 nM. PLK1-IN-12 shows more selective for PLK1 than PLK2 (IC₅₀: >10000 nM) and PLK3 (IC₅₀: 3953 nM). PLK1-IN-12 exhibits anticancer potency across a broad spectrum of cell lines. PLK1-IN-12 can be used in anti-leukemia research .

HY-15160C

TAK-960 monohydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 monohydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 monohydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 monohydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-12137R

Volasertib (Standard)	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (Standard) is the analytical standard of Volasertib. This product is intended for research and analytical applications. Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .

HY-173212

PLK1-IN-13	Polo-like Kinase (PLK) c-Myc Apoptosis	Cancer
PLK1-IN-13 is a selective and orally active *PLK1* inhibitor (IC₅₀: 0.27 nM). PLK1-IN-13 also inhibits PLK2 (IC₅₀: 12.72 nM) and PLK3 (IC₅₀: 4.12 nM). PLK1-IN-13 arrests cell at G2 phase, induces apoptosis and down-regulates the transcription of the proliferation-related oncogene c-MYC. PLK1-IN-13 inhibits tumor growth, and can be used for research of acute myeloid leukemia (AML) .

HY-176734

CZL-S092	Polo-like Kinase (PLK)	Cancer
CZL-S092 is a *PLK4* inhibitor with an IC₅₀ value of 0.9 nM and excellent selectivity over other *PLK4* family members (PLK1, PLK2, and PLK3). CZL-S092 exhibits anti-neuroblastoma activity in vitro (IMR-32 cells, IC₅₀ = 1.143 μM). CZL-S092 inhibits cell migration and halts the cell cycle and induces apoptosis. CZL-S092 can be used in studies of various cancers including neuroblastoma cancer .

Cat. No.	Product Name	Type

HY-110002

LFM-A13 1 Publications Verification	Biochemical Assay Reagents
LFM-A13 is a potent BTK, JAK2, *PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research ^[3]

Wortmannin 135+ Cited Publications SL-2052; KY-12420	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic
Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible *PI3K* inhibitor with an IC₅₀ of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and *Plk3* with IC₅₀s of 5.8 and 48 nM, respectively ^[3].

Wortmannin (Standard) SL-2052 (Standard); KY-12420 (Standard)	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Organoid Reference Standards PI3K Polo-like Kinase (PLK) Autophagy Antibiotic
Wortmannin (Standard) is the analytical standard of Wortmannin. This product is intended for research and analytical applications. Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively ^[3].

Cat. No.	Compare	Product Name	Species	Source

HY-P702889

	PLK3 Polo Box Domain Protein, Human (MBP, His) CNK; FNK; PRK	Human	E. coli
	PLK3 Polo Box Domain Protein, Human (MBP, His) is the recombinant human-derived PLK3 Polo Box Domain, expressed by E. coli , with C-6*His, N-MBP labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Plk3 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Plk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Plk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

PLK3 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PLK3 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Plk3 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Plk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks